• small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7

2017 News Releases

Webcast ImageWebcast
Mimedx Group Inc. Shareholder Call (Replay)
Dec 13, 2017 at 10:30 a.m. ET
Mimedx Group Inc. Shareholder Call
Wednesday, December 13, 2017 10:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
Dec 14, 2017MiMedx Adds New Materials To Its Website Exposing Misinformation Disseminated Through Short Sellers
MARIETTA, Ga., Dec. 14, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that it has posted additional materials on the Company's website that further expose the misinformation disseminated through short sellers. The new materials can be found on the MiMedx we... 
Printer Friendly Version
Dec 13, 2017MiMedx Forecasts 2018 Revenue To Be In The Range Of $383 Million To $387 Million
MARIETTA, Ga., Dec. 13, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today its guidance for full year 2018. Full Year 2018 Guidance Highlights: The Company's full year 2018 expectations include: Revenue estimated between $383 to $387 million Gross p... 
Printer Friendly Version
Dec 12, 2017MiMedx Announces Release Of 2018 Guidance And Shareholder Conference Call
MARIETTA, Ga., Dec. 12, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that its 2018 Guidance will be released before the opening of the market on Wednesday, December 13, 2017.  MiMedx will host a live broadcast of its Guidance conference call on Wednesday, Dece... 
Printer Friendly Version
Dec 06, 2017Two Independent Poster Abstracts Highlighting The Clinical Efficacy of MiMedx Allografts are Recognized at The 2017 Desert Foot Conference
MARIETTA, Ga., Dec. 6, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today that the Company's products were recognized at the recently completed 2017 Desert Foot, The Annual Multi-Disciplinary Diabetes Limb Salvage Conference Honoring Our Federal Services Healthcare... 
Printer Friendly Version
Nov 30, 2017MiMedx Announces Expectation To Exceed Top End of Fourth Quarter Revenue Guidance Of $88 Million
MARIETTA, Ga., Nov. 30, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today its preliminary expectation for fourth quarter of 2017 revenue to exceed the $88 million high end of its fourth quarter revenue guidance range. Parker H. "Pete" Petit, Chairman and CEO, ... 
Printer Friendly Version
Nov 30, 2017MiMedx Issues Shareholder Letter Detailing The Illegal Short Selling The Company Is Experiencing
MARIETTA, Ga., Nov. 30, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that it has posted on the Company's website a letter to MiMedx Shareholders that provides a detailed discussion of the illegal short selling and how this is being managed by the Company. T... 
Printer Friendly Version
Nov 21, 2017MiMedx Provides Update On Its Reimbursement Coverage
MARIETTA, Ga., Nov. 21, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, provided a reimbursement update today. Parker H. "Pete" Petit, Chairman and Chief Executive Officer, said "With the publication of the Venous Leg Ulcer (VLU) study earlier this quarter, one of the nation... 
Printer Friendly Version
Nov 21, 2017MiMedx to Present at the 29th Annual Piper Jaffray Healthcare Conference
MARIETTA, Ga., Nov. 21, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that it will present at the 29th Annual Piper Jaffray Healthcare Conference in New York, New York.  Parker H.  "Pete" Petit, Chairman and CEO, Michael J. Senken, Chief Financial Officer,  Chr... 
Printer Friendly Version
Nov 17, 2017MiMedx Market Leadership Well Positioned In Light Of FDA New Guidance Document
MiMedx reiterates Fourth Quarter and Full Year 2017 Guidance MARIETTA, Ga., Nov. 17, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that the Food and Drug Administration (FDA) issued numerous Final and Draft Guidance documents.  Among them was the final Guida... 
Printer Friendly Version
Nov 14, 2017MiMedx Adds New Materials To Its Website Exposing Misinformation Disseminated Through Short Sellers
MARIETTA, Ga., Nov. 20, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that it has posted additional materials on the Company's website that further expose the misinformation disseminated through short sellers. The new materials can be found on the MiMedx we... 
Printer Friendly Version
Nov 08, 2017MiMedx to Present at Jefferies 2017 London Healthcare Conference
MARIETTA, Ga., Nov. 8, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today that it will present at Jefferies 2017 London Healthcare Conference in London, UK. Parker H. "Pete" Petit, Chairman & CEO, Michael J. Senken, Chief Financial Officer, Christopher M. Cashm... 
Printer Friendly Version
Nov 08, 2017MiMedx To Webcast Its Investor's Day Conference on November 30, 2017
MARIETTA, Ga., Nov. 8, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today that it will be hosting and webcasting its Investor's Day Conference on Thursday, November 30, 2017. The conference will be held in New York City.    The Company reported that "Pete" Peti... 
Printer Friendly Version
Nov 02, 2017MiMedx To Present At The Canaccord|Genuity Medical Technology And Diagnostics Forum
MARIETTA, Ga., Nov. 2, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today that it will present at the Canaccord|Genuity Forum in New York, NY.  Parker H. "Pete" Petit, Chairman and CEO, and Bill Taylor, President & COO, are scheduled to present on Thursday, Nov... 
Printer Friendly Version
Nov 01, 2017MiMedx Agrees To Lawsuit Settlement With Halo Wound Solutions
MARIETTA, Ga., Nov. 1, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that the Company has agreed to a confidential settlement of the lawsuit the Company filed against BioResolutions LLC d/b/a Halo Wound Solutions (Halo) and one of the Halo executives. MiMed... 
Printer Friendly Version
Oct 30, 2017MiMedx CEO Replies to Fraudulent Information About The Company
MARIETTA, Ga., Oct. 30, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today that the Company's Chairman and Chief Executive Officer, Parker H. "Pete" Petit,  has replied directly to shortseller Marc Cohodes' letter to Mr. Petit dated October 27, 2017. In his letter,... 
Printer Friendly Version
Oct 27, 2017MiMedx Exposes Content of a Short Seller Website Dedicated to Posting Defamatory and False Information About The Company
MARIETTA, Ga., Oct. 27, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today that the Company has become aware that shortseller Marc Cohodes has launched a website dedicated solely to posting defamatory and false information regarding MiMedx.  As part of this launch,... 
Printer Friendly Version
Oct 26, 2017MiMedx Announces Record Results For Third Quarter Of 2017 And Raises Full Year Revenue Guidance
MIMEDX OPERATING INCOME GROWS 88% ON 31% REVENUE GROWTH RECORD CASH FLOW FROM OPERATIONS OF $18.0 MILLION MARIETTA, Ga., Oct. 26, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today its record results for the third quarter of 2017. Third Quarter 2017 Financi... 
Printer Friendly Version
Oct 24, 2017MiMedx Adds New Materials To Its Website Exposing Misinformation Disseminated Through Short Seller Attacks
MARIETTA, Ga., Oct. 24, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that it has posted additional materials on the Company's website that further expose the misinformation disseminated through short seller attacks. The new materials can be found on the Mi... 
Printer Friendly Version
Oct 18, 2017New Clinical Evidence And A Landmark VLU Study To Be Presented At SAWC Fall Meeting
MiMedx Regenerative Wound Care Products Highlighted in Presentations and Eight Poster Abstracts MARIETTA, Ga., Oct. 18, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today that eight poster abstracts showing the clinical and cost effective healing resul... 
Printer Friendly Version
Oct 17, 2017MiMedx Warns Of Fake Emails
MARIETTA, Ga., Oct. 17, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, warned today that certain individuals or entities not associated with the Company are establishing fake email accounts to impersonate executives at the Company. The Company is aware of at least one insta... 
Printer Friendly Version
Oct 17, 2017MiMedx Notified By FDA That It Can Proceed With Phase 2B Investigational New Drug Clinical Trial For Osteoarthritis Of The Knee
MARIETTA, Ga., Oct. 17, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today that the Company has been notified by the Food and Drug Administration (FDA) that its Investigational New Drug (IND) Phase 2B clinical study for osteoarthritis of the knee may proceed. Th... 
Printer Friendly Version
Oct 16, 2017MiMedx Announces Release Date for 2017 Third Quarter Results
MARIETTA, Ga., Oct. 16, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that its results for the third quarter ended September 30, 2017, will be released before the opening of the market on Friday, October 27, 2017.  MiMedx will host a live broadcast of its third... 
Printer Friendly Version
Oct 11, 2017Multicenter Randomized Controlled VLU Clinical Study Published in the International Wound Journal Demonstrates Significantly Higher Healing Rates of MiMedx EpiFix®
MIMEDX REITERATES ITS EXPECTATION FOR THIS STUDY TO EXPAND THE COMPANY'S VLU INSURANCE COVERAGE BY AN ADDITIONAL $75 MILLION TO $150 MILLION ANNUAL REVENUE OPPORTUNITY MIMEDX EPIFIX SHOWED VLU HEALING RATES OF 60% AT 12 WEEKS AND 71% AT 16 WEEKS MARIETTA, Ga., Oct. 11, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected ... 
Printer Friendly Version
Oct 10, 2017MiMedx Announces Third Quarter Revenues Of $84.6 Million Exceeds Guidance By More Than 5 Percent
MiMedx To Host Conference Call on Wednesday, October 11, 2017 at 10:30AM Eastern Time MARIETTA, Ga., Oct. 10, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today its preliminary revenue results for the third quarter of 2017. Third Quarter 2017 Revenue Highlight... 
Printer Friendly Version
Oct 10, 2017MiMedx Adds New Materials To Its Website Exposing Misinformation Disseminated Through Short Seller Attacks
MARIETTA, Ga., Oct. 13, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that it has posted additional materials on the Company's website that further expose the misinformation disseminated through short seller attacks. The new materials can be found on the Mi... 
Printer Friendly Version
Oct 09, 2017MiMedx Board of Directors Authorizes $10 Million Increase to the Company's Share Repurchase Program
MARIETTA, Ga., Oct. 9, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today the decision of its Board of Directors to authorize a $10 million increase in the Company's Share Repurchase Program. This action by the MiMedx Board of Directors authorizing the additiona... 
Printer Friendly Version
Oct 06, 2017MiMedx to Present at the Janney Osteoarthritis Pain Conference
MARIETTA, Ga., Oct. 6, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that it will present at the Janney Osteoarthritis Pain Conference in New York, New York.  Michael J. Senken, Chief Financial Officer and Mark Landy, SVP-Strategic Initiatives, are scheduled to... 
Printer Friendly Version
Oct 04, 2017MiMedx Files Lawsuit Related To Short Seller Attacks
MARIETTA, Ga., Oct. 4, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that the Company and one of its employees have filed a lawsuit against Viceroy Research and Sparrow Fund Research LP a/k/a Aurelius Value, John Fichthorn, BR Dialectic Capital Management, LLC,... 
Printer Friendly Version
Oct 03, 2017Dr. Gloria Matthews Joins MiMedx As Its Senior Vice President Of Research And Development
MIMEDX REAFFIRMS LATEST THIRD QUARTER OF 2017 REVENUE EXPECTATIONS MARIETTA, Ga., Oct. 3, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that Dr. Gloria Matthews has joined the Company as its Senior Vice President, Research and Development.  Dr. Matthews will... 
Printer Friendly Version
Oct 02, 2017Court Sets the Trial Date for MiMedx Patent Infringement Lawsuit Against MTF, Medline and Liventa
MARIETTA, Ga., Oct. 2, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that the United States District Court for the Northern District of Georgia has set a trial date of January 22, 2018 for the Company's patent infringement lawsuit against Musculoskeletal Transp... 
Printer Friendly Version
Oct 02, 2017MiMedx Completes Divestiture Of Its Stability Biologics Subsidiary
MARIETTA, Ga., Oct. 2, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that it has completed the previously communicated divestiture of the Company's subsidiary, Stability Biologics LLC (f/k/a Stability Inc.), back to the former stockholders of Stability Inc. ... 
Printer Friendly Version
Sep 29, 2017MiMedx Publishes Document on its Website Exposing False and Misleading Information Distributed By Viceroy Research and Aurelius Value
MARIETTA, Ga., Sept. 29, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that it has published a document on the Company's website exposing the false and misleading information distributed by Viceroy Research and Aurelius Value in their articles on MiMedx. Vi... 
Printer Friendly Version
Sep 26, 2017MiMedx Agrees To Lawsuit Settlement With Terminated Employee
MARIETTA, Ga., Sept. 26, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that the Company has agreed to a confidential lawsuit settlement from one terminated employee. MiMedx has settled its lawsuit with former employee, Harold Purdy.  In this settlement, Mr.... 
Printer Friendly Version
Sep 21, 2017MiMedx Files Lawsuit Against The Capitol Forum
MARIETTA, Ga., Sept. 21, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that it is filing a lawsuit for libel, slander, defamation, false light, tortious interference with business relations, and violations of the Lanham Act against The Capitol Forum.  On Se... 
Printer Friendly Version
Sep 21, 2017MiMedx provides Information on Its Interaction With The SEC
MARIETTA, Ga., Sept. 21, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today its interactions with the Securities and Exchange Commission (SEC). First, as is disclosed in the Company's public filings, the Company already satisfactorily addressed a comment letter ... 
Printer Friendly Version
Sep 20, 2017MiMedx Responds To Deceptive Short Seller Reports
MARIETTA, Ga., Sept. 20, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, responds to deceptive short seller articles published earlier today.   Earlier today, two short seller articles, one by Viceroy Research and the other by Aurelius Value, were published on MiMedx. Parker ... 
Printer Friendly Version
Sep 19, 2017MiMedx To Host Shareholder Call On September 21, 2017 To Update Progress On Various Strategic Initiatives And Respond To Topics Requested By Shareholders
MARIETTA, Ga., Sept. 19, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today it will be hosting a webcast on Thursday, September 21, 2017 beginning at 10:30 a.m. Eastern Time to discuss numerous strategic initiatives and provide in-depth information on other key topi... 
Printer Friendly Version
Sep 19, 2017MiMedx Files With The FDA To Initiate The Company's Investigational New Drug Phase 2 Clinical Trial For Osteoarthritis Of The Knee
MARIETTA, Ga., Sept. 19, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today that the Company has filed with the Food and Drug Administration (FDA) to initiate its Investigational New Drug (IND) Phase 2 clinical trial for osteoarthritis of the knee. The osteoart... 
Printer Friendly Version
Sep 18, 2017MiMedx to Present at Cantor Fitzgerald's Global Healthcare Conference
MARIETTA, Ga., Sept. 18, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today that it will present at Cantor Fitzgerald's Global Healthcare Conference in New York, New York.  Parker H. "Pete" Petit, Chairman and CEO, Michael J. Senken, Chief Financial Officer,  Chris... 
Printer Friendly Version
Sep 18, 2017MiMedx Patent Infringement Lawsuit Updates
MARIETTA, Ga., Sept. 18, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing proprietary human placental tissue allografts, announced today that the Company prevailed in its patent infringement lawsuit against Musculoskeletal Transplant Foundation, Inc. ("MTF"), Medline Industries, Inc. ("Medline") and Liventa Bioscience, Inc. ("Liventa") last month against motions for summary judg... 
Printer Friendly Version
Sep 13, 2017MiMedx Reiterates Its Third Quarter Revenue Expectation To Exceed $80 Million Despite Hurricane Irma
MiMedx Production Operations and Placenta Recovery Functions Operating Normally MARIETTA, Ga., Sept. 13, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today that the Company's production operations in Georgia and placenta recovery functions are operating normally... 
Printer Friendly Version
Sep 12, 2017MiMedx Recognized as Number 5 on Fortune Magazine's List of the 100 Fastest Growing Public Companies
MARIETTA, Ga., Sept. 12, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today that the Company has been recognized by Fortune Magazine as the fifth ranked company in Fortune's 2017 list of the top 100 fastest growing public companies.     The methodology utilized ... 
Printer Friendly Version
Sep 07, 2017MiMedx Notified By FDA That It Can Proceed With Phase 3 Investigational New Drug Clinical Trial For Achilles Tendonitis
MARIETTA, Ga., Sept. 7, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today that the Company has been notified by the Food and Drug Administration (FDA) that the Investigational New Drug (IND) Phase 3 Achilles Tendonitis clinical study may proceed. The Achilles ... 
Printer Friendly Version
Sep 07, 2017MiMedx Reports Further Developments in its Civil Litigation Against Former Employees
MARIETTA, Ga., Sept. 7, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today further developments since its August 17, 2017 press release in its civil litigation against several former sales employees.  Developments in Civil Litigation Against Terminated Employee... 
Printer Friendly Version
Sep 06, 2017MiMedx To Attend Morgan Stanley's 15th Annual Global Healthcare Conference
MARIETTA, Ga., Sept. 6, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today that it will attend Morgan Stanley's 15th Annual Global Healthcare Conference in New York, New York.  Parker H. "Pete" Petit, Chairman and CEO, Michael J. Senken, Chief Financial Officer,  C... 
Printer Friendly Version
Sep 05, 2017MiMedx Announces Its Expectations For Third Quarter Revenue To Exceed $80 Million And Surpass Its Previous Revenue Guidance
MARIETTA, Ga., Sept. 5, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today its expectation for third quarter of 2017 revenue to exceed the $80 million high end of its third quarter revenue guidance range. Parker H. Petit, Chairman and CEO, commented, "Revenue f... 
Printer Friendly Version
Aug 31, 2017MiMedx Reports MultiCenter randomized Controlled VLU Clinical Study Accepted for Publication in The International Wound Journal
Unparalleled Results of 60% healing at 12 Weeks and 71% Healing at 16 Weeks Expected to Expand VLU Insurance Coverage to an Additional $75 Million to $150 Million in annual Revenue Opportunity MARIETTA, Ga., Aug. 31, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced ... 
Printer Friendly Version
Aug 18, 2017MiMedx Signs Definitive Agreement to Divest Stability Biologics Subsidiary as Part of Company's Strategic Focus on Biopharma
MARIETTA, Ga., Aug. 18, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that it has signed a definitive agreement with the former stockholders of Stability Inc. to divest the Company's subsidiary, Stability Biologics LLC (f/k/a Stability Inc.) back to those stock... 
Printer Friendly Version
Aug 17, 2017MiMedx Provides Update on Litigation with Terminated Employees
MARIETTA, Ga., Aug. 17, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, provided an update on its litigation with certain former employees. As previously disclosed in the Company's quarterly report on Form 10-Q as filed with the Securities and Exchange Commission on July 31... 
Printer Friendly Version
Aug 09, 2017MiMedx Hits Milestone of One Million Allografts Distributed
MARIETTA, Ga., Aug. 9, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today that the Company has now distributed over 1,000,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of ... 
Printer Friendly Version
Aug 04, 2017MiMedx Files With The FDA To Initiate Its Investigational New Drug Achilles Tendonitis Phase 3 Clinical Trial
MARIETTA, Ga., Aug. 4, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today that the Company has filed with the Food and Drug Administration (FDA) to initiate its Investigational New Drug (IND) Phase 3 Achilles Tendonitis clinical study. The Achilles Tendonitis c... 
Printer Friendly Version
Aug 02, 2017MiMedx Reports Exceptional Results in Phase 2B Clinical Trial on the Use of AmnioFix® Injectable in the Treatment of Plantar Fasciitis
MARIETTA, Ga., Aug. 2, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today that it has closed enrollment in the Company's Plantar Fasciitis Investigational New Drug (IND) Phase 2B trial in accordance with an amendment filed with the Food and Drug Administration (FDA... 
Printer Friendly Version
Aug 02, 2017MiMedx Initiates Phase 3 Plantar Fasciitis Clinical Trial
MIMEDX TO HOST SHAREHOLDER CALL ON AUGUST 7, 2017 TO PRESENT THE STATUS OF VARIOUS CLINICAL STUDIES SUPPORTING ITS BIOPHARMACEUTICAL STRATEGY MARIETTA, Ga., Aug. 2, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today that the Company has initiated its Phase 3 Pla... 
Printer Friendly Version
Aug 01, 2017MiMedx To Present At The 37th Annual Canaccord|Genuity Growth Conference
MARIETTA, Ga., Aug. 1, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today that it will present at the 37th Annual Canaccord|Genuity Growth Conference  in  Boston, Massachusetts.  Parker H. "Pete" Petit, Chairman and CEO, Michael J. Senken, Chief Financial Officer, ... 
Printer Friendly Version
Jul 26, 2017MiMedx Announces Record Results For The Second Quarter Of 2017 And Raises Full Year Revenue Guidance
COMPANY RECORDS 33% REVENUE GROWTH AND A 309% INCREASE IN NET INCOME OVER Q2 2016 MARIETTA, Ga., July 26, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today its record results for the second quarter of 2017. Second Quarter 2017 Highlights Q2 2017 Revenu... 
Printer Friendly Version
Jul 13, 2017MiMedx Announces That Its Second Quarter Revenue Exceeds The Guidance Range
In the news release, MiMedx Announces That Its Second Quarter Revenue Exceeds The Guidance Range, issued 13-Jul-2017 by MiMedx Group, Inc. over PR Newswire, we are advised by the company that the second bullet under the "Second Quarter 2017 Revenue Highlights" section should read, "Q2 2017 Revenue grew 33% over Q2 2016 revenue" and the first sentence of the second full paragraph should read, in relevant part, "...a $19.1 million or 33% increase over 2016 second quarter revenue of $57.3 million."... 
Printer Friendly Version
Jul 05, 2017MiMedx Agreement With AvKARE Expires As Planned Following Completion Of Contract Wind-Down
MARIETTA, Ga., July 5, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that the Company's contract with AvKARE has expired as planned effective June 30, 2017. MiMedx and AvKARE began planning the wind-down of the contract in 2015, leading up to the final expirati... 
Printer Friendly Version
Jun 15, 2017Scientific And Clinical Review Confirms Potential Of MiMedx dHACM Allografts For Regenerative Applications In Orthopedics
dHACM Allografts Retain Growth Factors And Bioactive Proteins Shown To Regulate Activity Of Cell Types, Including Stem Cells, That Are Critical To Orthopedic Repair Of Injured And Diseased Tissue MARIETTA, Ga., June 15, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announce... 
Printer Friendly Version
Jun 13, 2017MiMedx Amniofix® data showing colorectal anastomotic leak rate reduction presented at ASCRS Meeting
MARIETTA, Ga., June 13, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today the presentation of new clinical data at the American Society of Colon and Rectal Surgeons 2017 Annual Scientific and Tripartite Meeting ("2017 ASCRS Annual Scientific Meeting"), showing  tha... 
Printer Friendly Version
Jun 01, 2017MiMedx to Present at the Jefferies 2017 Global Healthcare Conference
MARIETTA, Ga., June 1, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that it will present at the Jefferies 2017 Global Healthcare Conference in New York, New York.  Parker H. "Pete" Petit, Chairman and CEO, Michael J. Senken, Chief Financial Officer, Christopher M. Cashman, EV... 
Printer Friendly Version
May 18, 2017MiMedx To Attend The 14th Annual Craig-Hallum Institutional Investor Conference
MARIETTA, Ga., May 18, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that it will attend the 14th Annual Craig-Hallum Institutional Investor Conference in Minneapolis, Minnesota.  Parker H. "Pete" Petit, Chairman and CEO, Michael J. Senken, Chief Financial Officer, Christopher... 
Printer Friendly Version
May 01, 2017MiMedx Receives Innovative Technology Supplier of the Year Award from Vizient, Inc.
The largest member-Driven Health Care Performance Improvement Company recognizes MiMedx for its positive impact on patient care MARIETTA, Ga., May 1, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today it has received the Innovative Technology Supplier of the Year Award from Vizi... 
Printer Friendly Version
Apr 28, 2017MiMedx Announces Record Results For First Quarter Of 2017
Company records 36% revenue growth, 261% increase in Net Income and 51% increase in Adjusted Net Income* over Q1 2016 MARIETTA, Ga., April 28, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today its record results for the quarter ended March 31, 2017. First Quarter 2017 Hig... 
Printer Friendly Version
Apr 24, 2017MiMedx to Present at the European Wound Management Association Annual Conference
The Dynamic Impact of Epifix® Dehydrated Human Amnion/Chorion Membrane Allografts to be Presented at the Symposium MARIETTA, Ga., April 24, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today Company's participation in the European Wound Management Association ("EWMA") 2017 Confe... 
Printer Friendly Version
Apr 18, 2017MiMedx To Present At 5th Annual Cell & Gene Therapy Investor Day
MARIETTA, Ga., April 18, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that Dr. Mark Landy, Vice President – Strategic Initiatives, will represent the Company at the 5th Annual Cell & Gene Therapy Investor Day in Boston, Massachusetts.  The presentation will be conducted "... 
Printer Friendly Version
Apr 13, 2017MiMedx Announces First Quarter 2017 Revenue to Exceed High End of Guidance
Q1 2017 Revenue of $72.6 Million is 36% Increase Over Q1 2016 MARIETTA, Ga., April 13, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today its revenue results for the first quarter of 2017. First Quarter 2017 Revenue Highlights Revenue grew 36% over Q1 2016 revenue ... 
Printer Friendly Version
Apr 05, 2017The Use Of MiMedx Allografts From The Company's Multiple Product Families To Be Presented At SAWC Conference
Poster Abstracts, Booth Education and Symposia Demonstrate Clinical and Cost Effective Results of MiMedx EpiFix®, AmnioFix®, EpiCord®, AmnioCord® and AmnioFill® Allografts in Healing Chronic and Acute Wounds MARIETTA, Ga., April 5, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine and biopharmaceutical company utilizing human placental tissue allografts and patent-protected processes to develop and market advanced products and therapies for multiple sec... 
Printer Friendly Version
Mar 24, 2017MiMedx To Present At The 16th Annual Needham Healthcare Conference
MARIETTA, Ga., March 24, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine and biopharmaceutical company utilizing human placental tissue allografts and patent-protected processes to develop and market advanced products and therapies for multiple sectors of healthcare, announced today  that it will present at the Needham Healthcare Conference in New York, NY.  Parker H. "Pete" Petit, Chairman and CEO, Michael J. Senken, Chief Financial Officer, Christopher... 
Printer Friendly Version
Mar 19, 2017MiMedx Announces The Addition Of Luis A. Aguilar To Its Board Of Directors
NEWEST MIMEDX BOARD MEMBER IS FORMER COMMISSIONER OF THE U.S. SECURITIES & EXCHANGE COMMISSION MARIETTA, Ga., March 19, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine and biopharmaceutical company utilizing human placental tissue allografts and patent-protected processes to develop and market advanced products and therapies for multiple sectors of healthcare, announced today its Board of Directors has appointed Luis A. Aguilar, former Commissione... 
Printer Friendly Version
Mar 08, 2017MiMedx To Present At Canaccord's 12th Annual Musculoskeletal Conference
COMPANY ALSO TO EXHIBIT AT AMERICAN ASSOCIATION OF ORTHOPAEDIC SURGEONS (AAOS) MEETING MARIETTA, Ga., March 8, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human placental tissue allografts and other birth tissues, human skin and bone, and patent-protected processes and proprietary platforms to develop and market advanced products and therapies, announced today that it will present at Canaccord's 12th Annual Musculoskeletal Confer... 
Printer Friendly Version
Mar 02, 2017MiMedx to Host Shareholder call on March 9, 2017 to present various strategic and tactical initiatives to shareholders
MARIETTA, Ga., March 2, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human placental tissue allografts and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today it will be hosting a webcast on Thursday, March 9, 2017 beginning at 10:30 a.m. Eastern Time to discuss numerous strategi... 
Printer Friendly Version
Mar 01, 2017MiMedx Audit Committee Announces Completion Of Its Investigation
AUDIT COMMITTEE FINDS NO WRONGDOING BY MIMEDX MANAGEMENT MARIETTA, Ga., March 1, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human placental tissue allografts and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that the Audit Committee of its Board of Directors has comple... 
Printer Friendly Version
Feb 23, 2017MiMedx Announces 2016 Record Results
MARIETTA, Ga., Feb. 23, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, today announced its record results for the fourth quarter and full year ended December 31, 2016. Full Year 2016 Highlights are: Revenue is a ... 
Printer Friendly Version
Feb 16, 2017MiMedx Announces Release Date for 2016 Full Year Results
MARIETTA, Ga., Feb. 16, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that its results for the fourth quarter and year ended December 31, 2016, will be released before the opening of the market on Thursd... 
Printer Friendly Version
Feb 07, 2017Benefits Of MiMedx dHACM Allograft Chronicled In Multiple Articles In February 2017 Supplement Edition Of Annals of Plastic Surgery
ARTICLES BY RENOWNED PHYSICIANS DEMONSTRATE THE CLINICAL BENEFITS OF dHACM ALLOGRAFTS IN BURN MANAGEMENT AND THE TREATMENT OF DIFFICULT TO HEAL WOUNDS MARIETTA, Ga., Feb. 7, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human placental tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthc... 
Printer Friendly Version
Feb 06, 2017MiMedx Board of Directors Authorizes $10 Million Increase to the Company's Share Repurchase Program
MARIETTA, Ga., Feb. 6, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today the decision of its Board of Directors to authorize an increase in the Company's Share Repurchase Program. This action by the MiMe... 
Printer Friendly Version
Feb 03, 2017MiMedx Comments On FDA Decision Not To Finalize HCT/P Guidance Documents This Year
MARIETTA, Ga., Feb. 3, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, commented today regarding the Food and Drug Administration's ("FDA's") recently published 2017 calendar year guidance agenda. The tissue-related Guida... 
Printer Friendly Version
Jan 24, 2017Scientific Study Confirms MiMedx dHACM Allograft Promotes Cardiac Repair Following Myocardial Infarction
STUDY DEMONSTRATES THAT dHACM TREATMENT EFFECTS IMPROVED CELL SURVIVAL, ENHANCED VASCULARIZATION, AND RECRUITMENT OF AUTOLOGOUS STEM CELLS WITHIN INFARCTED CARDIAC TISSUE MARIETTA, Ga., Jan. 24, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Denta... 
Printer Friendly Version
Jan 09, 2017MiMedx Fourth Quarter 2016 Revenue in Upper Range of Guidance
$246.8 Million Full Year 2016 Revenue is a 32% Increase Over 2015 and $71.6 Million Q4 2016 Revenue is a 38% Increase Over Q4 2015 MARIETTA, Ga., Jan. 9, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, today announced ... 
Printer Friendly Version
Jan 03, 2017MiMedx to Present at 35th Annual J.P. Morgan Healthcare Conference
MARIETTA, Ga., Jan. 3, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today the schedule for its presentation at the 35th Annual J.P. Morgan Healthcare Conference.  Parker H. "Pete" Petit, Chairman and CEO, Wil... 
Printer Friendly Version

Products

CONTACT US

888.543.1917